Key facts
- It has raised $14.1M; the latest was Later Stage VC ($14.1M) in Dec 2025.
- Notable investors include Lapam Capital, Zhongguancun Development Venture Capital Fund, Beijing Zhongguancun Venture Capital Development, Beijing Innovation Industry Investment, Daoyuan Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for BroadenBio
- ·The full record, as it builds
Funding rounds
No funding rounds for BroadenBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BroadenBio
Developer of a biological technology designed to overcome tumors and immune diseases. The company focuses on research and development of biotechnology for curing tumors and immune diseases and provides pharmaceutical products for cancer diseases, enabling clients to receive efficient treatment and improve health conditions.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Website
- broadenbio.com/
- Ownership
- Privately Held (backing)
BroadenBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BroadenBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BroadenBio in its N-PORT filings yet. We sweep new filings monthly.